Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide.

ABSTRACT:

Background

Androgen receptor (AR) is expressed in approximately 70% of breast tumors. Recent studies increasingly support AR as a potential therapeutic target of AR-positive breast cancer. We have previously reported that deubiquitinase USP14 stabilizes AR proteins by deubiquitination and USP14 inhibition results in inhibition of cell growth and tumor progression in AR-positive prostate cancer and breast cancer. The current study aims to explore the anticancer effect of a treatment combining AR antagonist enzalutamide with USP14 inhibition on breast cancer cells.

Methods

The combining effects of enzalutamide and USP14 inhibition on breast cancer cell proliferation and apoptosis and associated cell signaling were evaluated in vitro and in vivo.

Results

USP14 inhibition

SUBMITTER: Xia X 

PROVIDER: S-EPMC6534920 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature